Mutagenic Mapping Suggests a Novel Binding Mode for Selective Agonists of M1 Muscarinic Acetylcholine Receptors
- 11 November 2008
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Molecular Pharmacology
- Vol. 75 (2), 331-341
- https://doi.org/10.1124/mol.108.050963
Abstract
Point mutations and molecular modeling have been used to study the activation of the M(1) muscarinic acetylcholine receptor (mAChR) by the functionally selective agonists 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42), and 1-[3-(4-butyl-1-piperidinyl)propyl]-3,4-dihydro-2(1H)-quinolinone (77-LH-28-1), comparing them with N-desmethylclozapine (NDMC) and acetylcholine (ACh). Unlike NDMC and ACh, the activities of AC-42 and 77-LH-28-1 were undiminished by mutations of Tyr404 and Cys407 (transmembrane helix 7), although they were reduced by mutations of Tyr408. Signaling by AC-42, 77-LH-28-1, and NDMC was reduced by L102A and abolished by D105E, suggesting that all three may interact with transmembrane helix 3 at or near the binding site Asp105 to activate the M(1) mAChR. In striking contrast to NDMC and ACh, the affinities of AC-42 and 77-LH-28-1 were increased 100-fold by W101A, and their signaling activities were abolished by Y82A. Tyr82 and Leu102 contact the indole ring of Trp101 in a structural model of the M(1) mAChR. We suggest the hypothesis that the side chain of Trp101 undergoes conformational isomerization, opening a novel binding site for the aromatic side chain of the AC-42 analogs. This may allow the positively charged piperidine nitrogen of the ligands to access the neighboring Asp105 carboxylate to activate signaling following a vector within the binding site that is distinct from that of acetylcholine. NDMC does not seem to use this mechanism. Subtype-specific differences in the free energy of rotation of the side chain and indole ring of Trp101 might underlie the M(1) selectivity of the AC-42 analogs. Tryptophan conformational isomerization may open up new avenues in selective muscarinic receptor drug design.Keywords
This publication has 34 references indexed in Scilit:
- Characterization of a CNS penetrant, selective M1muscarinic receptor agonist, 77‐LH‐28‐1British Journal of Pharmacology, 2008
- High-Resolution Crystal Structure of an Engineered Human β 2 -Adrenergic G Protein–Coupled ReceptorScience, 2007
- Functional Analysis of Transmembrane Domain 2 of the M1 Muscarinic Acetylcholine ReceptorPublished by Elsevier BV ,2007
- How Different are Structurally Flexible and Rigid Binding Sites? Sequence and Structural Features Discriminating Proteins that Do and Do not Undergo Conformational Change upon Ligand BindingJournal of Molecular Biology, 2006
- Structural Requirements of Transmembrane Domain 3 for Activation by the M1Muscarinic Receptor Agonists AC-42, AC-260584, Clozapine, andN-Desmethylclozapine: Evidence for Three Distinct Modes of Receptor ActivationMolecular Pharmacology, 2006
- Transmembrane Domains 4 and 7 of the M1Muscarinic Acetylcholine Receptor Are Critical for Ligand Binding and the Receptor Activation SwitchPublished by Elsevier BV ,2001
- The functional role of the binding site aspartate in muscarinic acetylcholine receptors, probed by site-directed mutagenesisEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Backbone-dependent Rotamer Library for Proteins Application to Side-chain PredictionJournal of Molecular Biology, 1993
- Muscarinic Receptor SubtypesAnnual Review of Pharmacology and Toxicology, 1990
- CHARMM: A program for macromolecular energy, minimization, and dynamics calculationsJournal of Computational Chemistry, 1983